Bøger af Dileep Kumar

"The Leadership Blueprint: A Guide to Brilliance for Teens and Young Adults" is a guide designed to inspire, educate, and empower emerging leaders. The book draws from the author's years of experience mentoring young adults, offering invaluable insights into cultivating essential leadership skills like empathy, resilience, and innovation.Beyond the usual leadership rhetoric, the book delves into the unique challenges today's teens face and provides practical strategies to navigate this intricate journey. It also underscores the value of personal development, self-awareness, and introspection, building a foundation for effective leadership.From understanding the power of influence to the importance of creativity and innovation in problem-solving, this book offers comprehensive guidance for young leaders in the making. "The Leadership Blueprint" will inspire teens and young adults to step up and lead and equip them with the tools to make a significant difference in their worlds. This is an essential read for young minds ready to step into their leadership potential and leave a lasting impact.

This book explains the fundamental characteristics and biofunctionality of Alzheimer¿s Disease drug targets and provides up-to-date information on the full range of their biomedical applications. An introductory section gives an overview of the recent developments related to drug targets identified and studied related to Alzheimer¿s Disease and key developments from preclinical and clinical studies focusing on various molecular targets related to AD and dementia by subject experts all around the globe. Here, individual chapters address the progress and perspectives in human and non-human research, role of various biomarkers as an overview, advanced gene therapy, and novel compounds for therapeutic targets for Alzheimer¿s disease. The book will be essential reading for graduate students, scientists, and engineers in any of the biomedical research fields in which efforts are being made to utilize novel drug targets and develop effective strategies for new drug targeting and delivery in Alzheimer¿s disease treatment.

Self-development is a journey of personal growth and improvement. It's about becoming the best version of yourself and living a life that's fulfilling, purposeful, and meaningful. In this book, you will discover practical tips and strategies that will help you unlock your full potential and achieve your goals.You'll learn how to develop a growth mindset, overcome limiting beliefs, and cultivate positive habits. You'll also discover how to set clear and achievable goals, manage your time effectively, and deal with setbacks and challenges.The book will guide you through various aspects of self-development, including emotional intelligence, communication skills, and resilience. You'll gain insights into how to build strong relationships, handle stress, and maintain a positive outlook on life.With inspiring stories and actionable advice, this book will help you transform your life and achieve the success and happiness you desire. Whether you're looking to boost your career, improve your health, or enhance your relationships, this book will provide you with the tools you need to reach your full potential.

Alzheimer's disease (AD), is a chronic neurodegenerative disease that causes senile decay of neurons It is the cause of 60¿70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. Genetic factors such as rare variants of TREM2(triggering receptor expressed on myeloid cells-2) strongly increase the risk of developing AD, confirming the role of microglia in AD pathogenesis. In the last 5 years, several studies have dissected the mechanisms by which TREM2, as well as its rare variants affect amyloid and tau pathologies and their consequences in both animal models and in human studies. In this review, we summarize increases in our understanding of the involvement of TREM2 and microglia in AD development that may open new therapeutic strategies targeting the immune system to influence AD pathogenesis.

Alzheimer's disease (AD) is the commonest sort of dementia. Pathologically, AD is characterized by amyloid plaques and neurofibrillary tangles within the brain, with associated loss of synapses and neurons, leading to cognitive deficits and eventually dementia. Amyloid-¿ (A¿) peptide and tau protein are the first components of the plaques and tangles, respectively. Within the decades since A¿ and tau were identified, the event of therapies for AD has primarily focused on A¿, but tau has received more attention in recent years, partially due to the failure of varied A¿-targeting treatments in clinical trials. During this article, we review the present status of tau-targeting therapies for AD. Given that tau pathology correlates better with cognitive impairments than do A¿ lesions, targeting of tau is expected to give more effective than A¿ clearance once the clinical symptoms are evident. With future improvements in diagnostics, these two hallmarks of the disease might be targeted prophylactically.